Switch theme
Sign up to access all valuation multiples
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
2005
95
LTM Revenue $22.9M
LTM EBITDA -$4.1M
$77.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cyclopharm has a last 12-month revenue (LTM) of $22.9M and a last 12-month EBITDA of -$4.1M.
In the most recent fiscal year, Cyclopharm achieved revenue of $17.7M and an EBITDA of -$7.4M.
Cyclopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cyclopharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $22.9M | XXX | $17.7M | XXX | XXX | XXX |
| Gross Profit | $16.5M | XXX | $11.5M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | -$4.1M | XXX | -$7.4M | XXX | XXX | XXX |
| EBITDA Margin | -18% | XXX | -42% | XXX | XXX | XXX |
| EBIT | -$4.9M | XXX | -$9.3M | XXX | XXX | XXX |
| EBIT Margin | -22% | XXX | -53% | XXX | XXX | XXX |
| Net Profit | -$4.8M | XXX | -$8.5M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | -48% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cyclopharm's stock price is AUD 1 (or $1).
Cyclopharm has current market cap of AUD 133M (or $85.7M), and EV of AUD 121M (or $77.8M).
See Cyclopharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $77.8M | $85.7M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cyclopharm has market cap of $85.7M and EV of $77.8M.
Cyclopharm's trades at 4.4x EV/Revenue multiple, and -10.5x EV/EBITDA.
Equity research analysts estimate Cyclopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cyclopharm has a P/E ratio of -17.8x.
See valuation multiples for Cyclopharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $85.7M | XXX | $85.7M | XXX | XXX | XXX |
| EV (current) | $77.8M | XXX | $77.8M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | -19.0x | XXX | -10.5x | XXX | XXX | XXX |
| EV/EBIT | -15.7x | XXX | -8.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.8x | XXX | -10.1x | XXX | XXX | XXX |
| EV/FCF | -13.7x | XXX | -8.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCyclopharm's last 12 month revenue growth is 60%
Cyclopharm's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Cyclopharm's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cyclopharm's rule of X is 132% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cyclopharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 60% | XXX | 60% | XXX | XXX | XXX |
| EBITDA Margin | -18% | XXX | -42% | XXX | XXX | XXX |
| EBITDA Growth | -221% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 132% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cyclopharm acquired XXX companies to date.
Last acquisition by Cyclopharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Cyclopharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cyclopharm founded? | Cyclopharm was founded in 2005. |
| Where is Cyclopharm headquartered? | Cyclopharm is headquartered in Australia. |
| How many employees does Cyclopharm have? | As of today, Cyclopharm has 95 employees. |
| Is Cyclopharm publicy listed? | Yes, Cyclopharm is a public company listed on ASX. |
| What is the stock symbol of Cyclopharm? | Cyclopharm trades under CYC ticker. |
| When did Cyclopharm go public? | Cyclopharm went public in 2007. |
| Who are competitors of Cyclopharm? | Similar companies to Cyclopharm include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Cyclopharm? | Cyclopharm's current market cap is $85.7M |
| What is the current revenue of Cyclopharm? | Cyclopharm's last 12 months revenue is $22.9M. |
| What is the current revenue growth of Cyclopharm? | Cyclopharm revenue growth (NTM/LTM) is 60%. |
| What is the current EV/Revenue multiple of Cyclopharm? | Current revenue multiple of Cyclopharm is 3.4x. |
| Is Cyclopharm profitable? | Yes, Cyclopharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cyclopharm? | Cyclopharm's last 12 months EBITDA is -$4.1M. |
| What is Cyclopharm's EBITDA margin? | Cyclopharm's last 12 months EBITDA margin is -18%. |
| What is the current EV/EBITDA multiple of Cyclopharm? | Current EBITDA multiple of Cyclopharm is -19.0x. |
| What is the current FCF of Cyclopharm? | Cyclopharm's last 12 months FCF is -$5.7M. |
| What is Cyclopharm's FCF margin? | Cyclopharm's last 12 months FCF margin is -25%. |
| What is the current EV/FCF multiple of Cyclopharm? | Current FCF multiple of Cyclopharm is -13.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
